REFRACTORY MULTIPLE MYELOMA

This early-phase study tests a new drug called OPN-6602, given alone or with another drug (dexamethasone), in people with multiple myeloma that has returned or stopped responding to at least three prior treatments. The main goal is to check the drug's safety and find the best dos…

This study tests a two-step treatment for people with multiple myeloma that has come back or stopped responding to other therapies. First, patients receive a drug called talquetamab to help control the cancer, followed by a one-time infusion of their own modified immune cells (ci…

This study tests whether adding dasatinib and quercetin to standard CAR-T therapy can better kill cancer cells in people with multiple myeloma that has returned or not responded to prior treatments. About 44 adults who have tried at least three other therapies will receive the dr…

This study tests whether adding daratumumab to a standard three-drug regimen can shrink tumors in people whose multiple myeloma has returned or stopped responding to prior treatments. About 43 adults aged 18 to 80 will receive the four drugs in cycles. The main goal is to see how…

This study tests whether a combination of elotuzumab, iberdomide, and dexamethasone can help control multiple myeloma that has returned or not responded to treatment, after patients have already received a CAR-T cell therapy called idecabtagene vicleucel. About 49 adults with rel…

This study tests whether the drug elranatamab, given after CAR T-cell therapy (idecabtagene vicleucel), can lower the chance of multiple myeloma worsening. It enrolls 32 adults with relapsed or refractory multiple myeloma. The goal is to see if this combination improves response …

This study tests a combination of four drugs (selinexor, carfilzomib, isatuximab, and dexamethasone) in people whose multiple myeloma has returned or stopped responding to treatment. The goal is to find a safe dose and see how well the combination controls the cancer. About 62 ad…

This study tests a combination of four drugs (isatuximab, belantamab mafodotin, pomalidomide, and dexamethasone) in 50 adults whose multiple myeloma has returned or stopped responding to treatment. The main goal is to see how many patients respond to this drug cocktail. This is n…

This early-phase study tests whether adding a personalized cancer vaccine (DC/MM fusion) to standard CAR-T cell therapy is safe and works better for people with multiple myeloma that has come back or not responded to treatment. About 25 adults will receive the vaccine along with …

This early-phase trial tests a new combination of two drugs—iberdomide and teclistamab—for people with multiple myeloma that has returned or no longer responds to standard treatments. The goal is to find the safest and most effective dose of iberdomide when used with teclistamab.…

This study tests different doses and schedules of belantamab mafodotin, a targeted therapy for multiple myeloma that has returned or not responded to prior treatments. The goal is to find a dosing plan that reduces serious eye problems while still controlling the cancer. About 62…

This study tests a new way of giving the drug elranatamab to people with multiple myeloma that has come back or stopped responding to other treatments. The goal is to see if giving the drug in an outpatient setting and on a less frequent schedule can reduce hospital stays and ser…

This study tests whether reducing the dose of the drug linvoseltamab after an initial good response can keep multiple myeloma under control while causing fewer side effects. About 30 adults with myeloma that has returned or stopped responding to other treatments will take part. R…

This early-phase trial tests a combination of three drugs—talquetamab, iberdomide, and dexamethasone—in 32 adults whose multiple myeloma has returned or stopped responding to prior treatments. The goal is to find the safest dose and check for side effects. Participants must have …

This study tests a combination of four drugs (iberdomide, daratumumab, carfilzomib, and dexamethasone) in adults whose multiple myeloma has come back or stopped responding to earlier treatments. The goal is to see if this mix can shrink the cancer to very low levels and keep it f…

This early-phase trial tests whether adding a new drug called SX-682 to standard myeloma medications is safe and tolerable for people whose cancer has come back or hasn't responded to prior therapy. SX-682 works by blocking signals that suppress the immune system, potentially hel…

This early-phase study tests a new treatment called TriPRIL CAR T cells for people with multiple myeloma that has come back or not responded to standard therapy. The main goal is to check safety and side effects in 18 adults. Participants first receive chemotherapy to prepare the…

This early-phase study tests a new type of cell therapy (BCMA-CD19 cCAR) in 12 people with multiple myeloma or plasmacytoid lymphoma that has come back or not responded to standard treatments. The main goal is to check safety and side effects. Participants receive a single infusi…

This study tests whether adding a drug called iberdomide to a standard treatment (belantamab mafodotin plus dexamethasone) is safe and works better for people with multiple myeloma that has come back or stopped responding to prior therapies. About 88 adults will take part. The go…

This early-stage study is testing whether a personalized cancer vaccine made from a patient's own cells, when combined with an immunotherapy drug called elranatamab, is safe and effective for treating multiple myeloma that has returned or stopped responding to standard treatments…

This early-stage trial is testing the safety and best dose of a new cell therapy for multiple myeloma that has returned or stopped responding to other treatments. Doctors take a patient's own immune cells, use CRISPR gene-editing technology to reprogram them to hunt down cancer c…

This study is testing a three-drug combination (MeziKD) for adults with multiple myeloma that has come back or stopped responding to other treatments and has spread to form tumors in soft tissues or organs. The goal is to see if this combination can shrink these tumors and contro…

This study looks at whether a personalized exercise program (aerobic and resistance training) done in the weeks before CAR-T therapy can improve physical fitness and quality of life in people aged 60 and older with multiple myeloma that has returned or not responded to treatment.…

This study tests if certain preventive treatments can reduce or prevent taste changes caused by a multiple myeloma drug called talquetamab. About 210 people with multiple myeloma will be randomly assigned to different preventive strategies. The goal is to improve quality of life …